EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)ÄquivalenzstudieOpen Access

Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy

Mikail Gögenur, Andreas Weinberger Rosen, Timothy Iveson, Rachel S Kerr, Mark P Saunders, Jim Cassidy, Josep Tabernero, Andrew Haydon, Bengt Glimelius, Andrea Harkin, Karen Allan, Sarah Pearson und 20 weitere

JAMA Surgery · 2024

DOI: 10.1001/jamasurg.2024.1555 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Surgery, 2024. Verfasst von Mikail Gögenur und 31 weiteren Autor:innen. Beteiligte Einrichtung: Center for Surgical Science, Department of Surgery, Zealand University Hospital, Køge, Denmark. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Colorectal Neoplasms, Oxaliplatin. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The timing of adjuvant chemotherapy after surgery for colorectal cancer and its association with long-term outcomes have been investigated in national cohort studies, with no consensus on the optimal time from surgery to adjuvant chemotherapy.

Objective

To analyze the association between the timing of adjuvant chemotherapy after surgery for colorectal cancer and disease-free survival. Design, Setting, and Participants This is a post hoc analysis of the phase 3 SCOT randomized clinical trial, from 244 centers in 6 countries, investigating the noninferiority of 3 vs 6 months of adjuvant chemotherapy. Patients with high-risk stage II or stage III nonmetastatic colorectal cancer who underwent curative-intended surgery were randomized to either 3 or 6 months of adjuvant chemotherapy consisting of fluoropyrimidine and oxaliplatin regimens. Those with complete information on the date of surgery, treatment type, and long-term follow-up were investigated for the primary and secondary end points. Data were analyzed from May 2022 to February 2024.

Intervention

In the post hoc analysis, patients were grouped according to the start of adjuvant chemotherapy being less than 6 weeks vs greater than 6 weeks after surgery. Main Outcomes and Measures The primary end point was disease-free survival. The secondary end points were adverse events in the total treatment period or the first cycle of adjuvant chemotherapy.

Results

A total of 5719 patients (2251 [39.4%] female; mean [SD] age, 63.4 [9.3] years) were included in the primary analysis after data curation; among them, 914 were in the early-start group and 4805 were in the late-start group. Median (IQR) follow-up was 72.0 (47.3-88.1) months, with a median (IQR) of 56 (41-66) days from surgery to chemotherapy. Five-year disease-free survival was 78.0% (95% CI, 75.3%-80.8%) in the early-start group and 73.2% (95% CI, 72.0%-74.5%) in the late-start group. In an adjusted Cox regression analysis, the start of adjuvant chemotherapy greater than 6 weeks after surgery was associated with worse disease-free survival (hazard ratio, 1.24; 95% CI, 1.06-1.46; P = .01). In adjusted logistic regression models, there was no association with adverse events in the total treatment period (odds ratio, 0.82; 95% CI, 0.65-1.04; P = .09) or adverse events in the first cycle of treatment (odds ratio, 0.77; 95% CI, 0.56-1.09; P = .13). Conclusions and Relevance In this international population of patients with high-risk stage II and stage III colorectal cancer, starting adjuvant chemotherapy more than 6 weeks after surgery was associated with worse disease-free survival, with no difference in adverse events between the groups. Trial Registration isrctn.org Identifier: ISRCTN59757862

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantColorectal NeoplasmsOxaliplatinAntimetabolites, AntineoplasticAgedFemaleHumansMaleMiddle AgedDisease-Free SurvivalNeoplasm StagingTime FactorsTime-to-TreatmentFluorouracil

Substanzen

OxaliplatinAntimetabolites, AntineoplasticFluorouracil

Autor:innen und Institutionen

  • Center for Surgical Science, Department of Surgery, Zealand University Hospital, Køge, Denmark.
  • Southampton University, Southampton, United Kingdom.
  • Department of Oncology, University of Oxford, Oxford, United Kingdom.
  • The Christie Hospital, Manchester, United Kingdom.
  • Glasgow Oncology Clinical Trials Unit, School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Centro de Investigación Biomédica en Red de Cáncer, Barcelona, Spain.

Zitieren

APA

Gögenur, M., Rosen, A. W., Iveson, T., Kerr, R. S., Saunders, M. P., Cassidy, J., Tabernero, J., Haydon, A., Glimelius, B., Harkin, A., Allan, K., Pearson, S., Boyd, K. A., Briggs, A. H., Waterston, A., Medley, L., Ellis, R., Dhadda, A. S., Harrison, M., …, & Holländer, N. H. (2024). Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy. JAMA Surgery. https://doi.org/10.1001/jamasurg.2024.1555

Vancouver

Gögenur M, Rosen AW, Iveson T, Kerr RS, Saunders MP, Cassidy J, et al. Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy. JAMA Surgery. 2024. doi:10.1001/jamasurg.2024.1555

BibTeX
@article{Ggenur2024,
  author = {Gögenur, Mikail and Rosen, Andreas Weinberger and Iveson, Timothy and Kerr, Rachel S and Saunders, Mark P and Cassidy, Jim and Tabernero, Josep and Haydon, Andrew and Glimelius, Bengt and Harkin, Andrea and Allan, Karen and Pearson, Sarah and Boyd, Kathleen A and Briggs, Andrew H and Waterston, Ashita and Medley, Louise and Ellis, Richard and Dhadda, Amandeep S and Harrison, Mark and Falk, Stephen and Rees, Charlotte and Olesen, Rene K and Propper, David and Bridgewater, John and Azzabi, Ashraf and Cunningham, David and Hickish, Tamas and Gollins, Simon and Wasan, Harpreet S and Kelly, Caroline and Gögenur, Ismail and Holländer, Niels Henrik},
  title = {Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy},
  journal = {JAMA Surgery},
  year = {2024},
  doi = {10.1001/jamasurg.2024.1555}
}
Kostenlos starten →